Introducing SRGel:

A State-of-the-art
Cancer Drug Delivery Platform

SRGel: Concentrated Long-acting, Local Release of AntiCancer Drugs

The SRGel platform is revolutionizing cancer treatment by enabling local sustained release of anticancer drugs at the tumor site, to maximize therapeutic effectiveness while minimizing systemic exposure and adverse effects. Built on natural and safe fatty acids, its unique hydrophobic, biocompatible and biodegradable gel-based composition is a true breakthrough in drug delivery.

As an injectable pre-filled single syringe, SRGel is easy to use, ready to be placed in any solid tumor, including surgically inaccessible tumors and/or chemo/radio-resistant tumors. 

The Power of SRGel

Easy to use

Easy-to-use

Pre-filled, ready-to-use syringe can be directly injected into any solid tumor on any part of the body during biopsy

Enhanced effectiveness

Enhanced effectiveness

Hydrophobic and solvent-free composition enables high drug loading (up to 50%)

Long-lasting release

Long-lasting release

Biodegradable SRGel starts releasing the drug in the first 24 hours, with continuous release up to 2 months after administration

Safe and well tolerated

Safe and well tolerated

Preclinical and clinical data with pipeline product, TumoCure, show tumor reduction with minimal to no systemic toxicity

Localized Action

Localized action 

Adheres to the tumor-injection site releasing the drug locally at concentrations 10 times higher than through systemic administration for maximum efficacy and minimal side effects

Multiple cancer indications

Multiple cancer
indications

Unique hydrophobic and inert gel can be mixed with more than 90% of existing anticancer drugs

Stability

Stability

SRGel has a long shelf-life of up to 24 months at room temperature, which lowers the shipping and storage limitations on caregivers and distributors

Avi Domb

“This is the first and only injectable gel that is free from solvents and made of fatty acids and is compatible with >90% of all drugs!”

Prof. Avi Domb, Intragel Co-Founder and Board of Directors, Co-inventor of the FDA-approved Gliadel® wafer for brain cancer.

How SRGel Works

Intragel is applied directly into the tumor

The drug is slowly released shrinking the tumor

The tumor is treated without side effects

Transforming Treatment in Multiple Cancer Indications

Intragel’s SRGel platform is highly scalable and can be applied to a wide range of anti-cancer drugs with suitability for various types of solid tumors. 

SRGel has successfully been combined with cisplatin, our flagship product, TumoCure, to treat head and neck, and lung cancer. Other drugs, such as paclitaxel and temozolamide, have also been successfully combined to treat other tumors. Future products in development aim to address other unmet medical needs in, colorectal, ovarian, and testicular cancer.

Supporting Scientific Literature

Intragel’s novel technology was developed based on years of research performed in the field. Below is key research published in leading peer-reviewed journals that supports the SRGel’s unique gel-based drug delivery system.

  1. Ghosh, R., Siman, P., & Domb, A. J. (2022). Poly(ester-anhydrides) with controlled molecular weight and structure. Polymer Advances and Technology, 33, 3774–3781.
  2. Ghosh, Radhakanta, Yuvaraj Arun, Peter Siman, and Abraham J Domb. “Synthesis of Aliphatic Polyanhydrides with Controllable and Reproducible Molecular Weight.” Pharmaceutics 14, no. 7 (2022): 1403. 
  3. Levy-Nissenbaum, E., Khan, W., Pawar, R. P., Tabakman, R., Naftali, E., Winkler, I., Kaufman, O., Klapper, L., & Domb, A. J. (2012). Pharmacokinetic and Efficacy Study of Cisplatin and Paclitaxel Formulated in a New Injectable Poly(sebacic-co-ricinoleic acid) Polymer. European Journal of Pharmaceutics and Biopharmaceutics, 82(1), 85-93. 
  4. Shikanov, A., Shikanov, S., Vaisman, B., Golenser, J., & Domb, A. J. (2011). Cisplatin Tumor Biodistribution and Efficacy after Intratumoral Injection of a Biodegradable Extended Release Implant. Chemotherapy Research and Practice, 2011, 175054. 
  1. Vaisman, B., Motiei, M., Nyska, A., & Domb, A. J. (2010). Biocompatibility and Safety Evaluation of a Ricinoleic Acid-Based Poly(ester-anhydride) Copolymer after Implantation in Rats. Journal of Biomedical Materials Research Part A, 92(2), 419-431. 
  2. Shikanov, A., & Domb, A. J. (2006). Poly(sebacic acid-co-ricinoleic acid) Biodegradable Injectable In Situ Gelling Polymer. Biomacromolecules, 7(1), 288-296. 
  3. Krasko, M. Y., & Domb, A. J. (2005). Hydrolytic Degradation of Ricinoleic-Sebacic-Ester-Anhydride Copolymers. Biomacromolecules, 6(4), 1877-1884. 
  4. Krasko, M. Y., Shikanov, A., Ezra, A., & Domb, A. J. (2003). Poly(ester anhydride)s Prepared by the Insertion of Ricinoleic Acid into Poly(sebacic Acid). Journal of Polymer Science: Part A: Polymer Chemistry, 41, 1059-1069.